Cargando…

Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy

INTRODUCTION: Tamoxifen, a nonsteroidal antiestrogenic agent, is used widely as adjunctive therapy for women with breast cancer. Most studies have found that the increased relative risk of developing endometrial cancer for women taking Tamoxifen is two to three times higher than that of an age-match...

Descripción completa

Detalles Bibliográficos
Autores principales: Jindal, Alka, Mohi, Manjit K., Kaur, Manjeet, Kaur, Balwinder, Singla, Risham, Singh, Shaunik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481741/
https://www.ncbi.nlm.nih.gov/pubmed/26167055
http://dx.doi.org/10.4103/0976-7800.158947
_version_ 1782378311875297280
author Jindal, Alka
Mohi, Manjit K.
Kaur, Manjeet
Kaur, Balwinder
Singla, Risham
Singh, Shaunik
author_facet Jindal, Alka
Mohi, Manjit K.
Kaur, Manjeet
Kaur, Balwinder
Singla, Risham
Singh, Shaunik
author_sort Jindal, Alka
collection PubMed
description INTRODUCTION: Tamoxifen, a nonsteroidal antiestrogenic agent, is used widely as adjunctive therapy for women with breast cancer. Most studies have found that the increased relative risk of developing endometrial cancer for women taking Tamoxifen is two to three times higher than that of an age-matched population. So we designed this study to assess the endometrial status in patients taking Tamoxifen for breast carcinoma. MATERIAL AND METHODS: The study was conducted at Govt. Medical College and Rajindra Hospital, Patiala, India. A total of 50 patients of Ca Breast taking Tamoxifen were selected as per study criterion and TVS performed. If endometrial thickness was more than 5 mm hysteroscopy and endometrial HPE was done and data analysed. RESULTS: On ultrasonography 35 patients (70%) had an endometrial thickness up to 5 mm. 15 patients (30%) had an endometrial thickness more than 5mm. Out of these, 11 patients, i.e. 22% of total, had an endometrial thickness of 5.1 to 10 mm and 2 patients, i.e. 4% of total had an endometrial thickness of more than 20 mm. Hysteroscopy was done on 11 patients. Out of these 8 patients had a normal hysteroscopic appearance whereas 3 patients had an abnormal hysteroscopic picture. Endometrial HPE of these 11 patients revealed 2 patients had secretory changes, 1 had polyp change, 1 had atrophic endometrium, 3 had simple endometrial hyperplasia, 1 had endometrial adenocarcinoma and 4 patients were reported to have scanty curetting. CONCLUSION: The duration of Tamoxifen therapy turned out to have a relationship with the incidence of endometrial carcinoma (P < 0.0001). Also, a relationship was observed between the duration of Tamoxifen therapy and symptom status of the patients (P < 0.0001). This correlation did not extend to duration of Tamoxifen therapy and endometrial thickness. (P = 0.190). This correlation did not extend to duration of Tamoxifen therapy and endometrial thickness. (P = 0.190).
format Online
Article
Text
id pubmed-4481741
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44817412015-07-12 Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy Jindal, Alka Mohi, Manjit K. Kaur, Manjeet Kaur, Balwinder Singla, Risham Singh, Shaunik J Midlife Health Original Article INTRODUCTION: Tamoxifen, a nonsteroidal antiestrogenic agent, is used widely as adjunctive therapy for women with breast cancer. Most studies have found that the increased relative risk of developing endometrial cancer for women taking Tamoxifen is two to three times higher than that of an age-matched population. So we designed this study to assess the endometrial status in patients taking Tamoxifen for breast carcinoma. MATERIAL AND METHODS: The study was conducted at Govt. Medical College and Rajindra Hospital, Patiala, India. A total of 50 patients of Ca Breast taking Tamoxifen were selected as per study criterion and TVS performed. If endometrial thickness was more than 5 mm hysteroscopy and endometrial HPE was done and data analysed. RESULTS: On ultrasonography 35 patients (70%) had an endometrial thickness up to 5 mm. 15 patients (30%) had an endometrial thickness more than 5mm. Out of these, 11 patients, i.e. 22% of total, had an endometrial thickness of 5.1 to 10 mm and 2 patients, i.e. 4% of total had an endometrial thickness of more than 20 mm. Hysteroscopy was done on 11 patients. Out of these 8 patients had a normal hysteroscopic appearance whereas 3 patients had an abnormal hysteroscopic picture. Endometrial HPE of these 11 patients revealed 2 patients had secretory changes, 1 had polyp change, 1 had atrophic endometrium, 3 had simple endometrial hyperplasia, 1 had endometrial adenocarcinoma and 4 patients were reported to have scanty curetting. CONCLUSION: The duration of Tamoxifen therapy turned out to have a relationship with the incidence of endometrial carcinoma (P < 0.0001). Also, a relationship was observed between the duration of Tamoxifen therapy and symptom status of the patients (P < 0.0001). This correlation did not extend to duration of Tamoxifen therapy and endometrial thickness. (P = 0.190). This correlation did not extend to duration of Tamoxifen therapy and endometrial thickness. (P = 0.190). Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4481741/ /pubmed/26167055 http://dx.doi.org/10.4103/0976-7800.158947 Text en Copyright: © Journal of Mid-life Health http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Jindal, Alka
Mohi, Manjit K.
Kaur, Manjeet
Kaur, Balwinder
Singla, Risham
Singh, Shaunik
Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
title Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
title_full Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
title_fullStr Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
title_full_unstemmed Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
title_short Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
title_sort endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on tamoxifen therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481741/
https://www.ncbi.nlm.nih.gov/pubmed/26167055
http://dx.doi.org/10.4103/0976-7800.158947
work_keys_str_mv AT jindalalka endometrialevaluationbyultrasonographyhysteroscopyandhistopathologyincasesofbreastcarcinomaontamoxifentherapy
AT mohimanjitk endometrialevaluationbyultrasonographyhysteroscopyandhistopathologyincasesofbreastcarcinomaontamoxifentherapy
AT kaurmanjeet endometrialevaluationbyultrasonographyhysteroscopyandhistopathologyincasesofbreastcarcinomaontamoxifentherapy
AT kaurbalwinder endometrialevaluationbyultrasonographyhysteroscopyandhistopathologyincasesofbreastcarcinomaontamoxifentherapy
AT singlarisham endometrialevaluationbyultrasonographyhysteroscopyandhistopathologyincasesofbreastcarcinomaontamoxifentherapy
AT singhshaunik endometrialevaluationbyultrasonographyhysteroscopyandhistopathologyincasesofbreastcarcinomaontamoxifentherapy